Organization
ImmuneOncia Therapeutics
4 clinical trials
Clinical trial
An Open-label, Single-arm, Phase 2 Study to Investigate the Efficacy and Safety of IMC-001 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal TypeStatus: Active (not recruiting), Estimated PCD: 2024-07-30
Clinical trial
An Open-Label, Dose-Escalation and Expansion, Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of IMC-002 in Patients With Advanced Cancer Failed to Standard TherapyStatus: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
A First-in-Human, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory LymphomasStatus: Completed, Estimated PCD: 2022-10-07
Clinical trial
PHASE 2 STUDY OF IMC-001 IN PATIENTS WITH METASTATIC OR LOCALLY ADVANCED TMB-H SOLID TUMORStatus: Not yet recruiting, Estimated PCD: 2025-12-01